Abstract
A recent study of Wilms’ tumors discovered a new X chromosome gene, Wilms’ tumor gene on the X chromosome (WTX), which was found to harbor small deletions and point mutations. WTX protein negatively regulates Wnt/ β-catenin signaling, and is considered a tumor-suppressor gene. One of the questions about the WTX gene is whether the genetic alterations of the WTX gene are specific to only Wilms’ tumors. To see whether somatic point mutations of WTX occur in other malignancies, we analyzed the WTX gene for the detection of mutations in 141 cancer tissues by a single-strand conformation polymorphism assay. The cancer tissues consisted of 47 gastric adenocarcinomas, 47 colorectal adenocarcinomas, and 47 hepatocellular carcinomas. Overall, we detected one WTX mutation in the colorectal carcinomas (1/47; 2.1%), but there was no WTX mutation in other cancers analyzed. The detected mutation was a missense mutation (c. 1117G > A (p.Ala373Thr)). Although the WTX mutation is common in Wilms’ tumors, our data indicate that it is rare in colorectal, gastric, and hepatocellular carcinomas. The data also suggest that deregulation of Wnt/ β-catenin signaling by WTX gene mutation may be a rare event in the pathogenesis of colorectal, gastric, and hepatocellular carcinomas.
Similar content being viewed by others
References
Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms’ tumor. Science. 2007;315:642–645. doi:10.1126/science.1137509.
Major MB, Camp ND, Berndt JD, et al. Wilms’ tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007;316:1043–1046. doi:10.1126/science/1141515.
Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res. 1999;59:3880–3882.
Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. Nuclear accumulation of beta-catenin protein in Wilms’ tumours. J Pathol. 2003;199:68–76. doi:10.1002/path.1248.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480. doi:10.1016/j.cell.2006.10.018.
Van der Flier LG, Sabates-Bellver J, Oving I, et al. The intestinal Wnt/TCF signature. Gastroenterology. 2007;132:628–632. doi:10.1053/j.gastro.2006.08.039.
de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95:8847–8851. doi:10.1073/pnas.95.15.8847.
Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999;18:3754–3760. doi:10.1038/sj.onc.1202769.
Kim HS, Lee JW, Soung YH, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology. 2003;125:708–715. doi:10.1016/S0016-5085(03)01059-X.
Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-9.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22. doi:10.1038/nrc969.
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331. doi:10.1016/S0092-8674(00)81871-1.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. doi:10.1126/science.1099314.
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790. doi:10.1056/NEJMoa051113.
Lee JW, Soung YH, Kim SY, et al. Mutational analysis of MYC in common epithelial cancers and acute leukemias. APMIS. 2006;114:436–439. doi:10.1111/j.1600-0463.2006.apm_383.x.
Jeong EG, Lee SH, Yoo NJ, Lee SH. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. APMIS. 2007;115:341–346. doi:10.1111/j.1600-0463.2007.apm_592.x.
Acknowledgments
This work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A080083).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoo, N.J., Kim, S. & Lee, S.H. Mutational Analysis of WTX Gene in Wnt/ β-Catenin Pathway in Gastric, Colorectal, and Hepatocellular Carcinomas. Dig Dis Sci 54, 1011–1014 (2009). https://doi.org/10.1007/s10620-008-0458-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0458-9